Short answer
Inhibikase Therapeutics, Inc. (IKT) filed an 8-K current report with the SEC on July 23, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Exhibit 99.1 furnished under Regulation FD, with disclosure excluded from Exchange Act Section 18 filing liabilities.
Inhibikase Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Exhibit 99.1 furnished under Regulation FD, with disclosure excluded from Exchange Act Section 18 filing liabilities
- No substantive business, financial, clinical, or operational information included in the provided text
Item EX-99.1 · Exhibit EX-99.1
- FDA Orphan Drug Designation for IKT-001 in PAH, supporting development of the lead candidate
- Potential benefits include clinical-trial tax credits, FDA fee exemptions, and seven years’ market exclusivity upon approval
- PAH affects approximately 50,000 Americans, establishing rare-disease eligibility and significant unmet need
- Global Phase 3 IMPROVE-PAH trial actively enrolling across approximately 180 sites
- Designation applies to imatinib’s active moiety, not specifically IKT-001’s formulation, limiting exclusivity certainty
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Inhibikase Therapeutics, Inc. 8-K filings
Get the next IKT 8-K as it lands
Follow IKT for push alerts, or ask the research agent what this filing means.